Jose Julio de Lucas Burneo

Dr. Jose Julio de Lucas Burneo


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Chemosphere
Verified
Journal Article
Closed access
CFCarmen Fajardo
Carmen Fajardo
CMCarmen Martín
Carmen Martín
GCGonzalo Costa
Gonzalo Costa
SRSebastián Sánchez-Fortún Rodríguez
Sebastián Sánchez-Fortún Rodríguez
CRCasilda Rodríguez
Casilda Rodríguez
MMMargarita Martín
Margarita Martín

1 July 2002 in Equine Veterinary Journal
Verified
Journal Article
Closed access
PDF file
MCM. Carretero
M. Carretero
CRC. Rodríguez
C. Rodríguez
MAM. I. San Andrés
M. I. San Andrés
PFP. Forés
P. Forés
JBJose Julio de Lucas Burneo
Jose Julio de Lucas Burneo
FGF. González
F. González

20 February 2003 in Journal of Veterinary Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
SWS. Waxman
S. Waxman
MAM. D. San Andrés
M. D. San Andrés
FGF. González
F. González
JBJose Julio de Lucas Burneo
Jose Julio de Lucas Burneo
MAM. I. San Andrés
M. I. San Andrés
CRC. Rodríguez
C. Rodríguez

16 April 2004 in Journal of Veterinary Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
JBJose Julio de Lucas Burneo
Jose Julio de Lucas Burneo
CRC Rodríguez
C Rodríguez
SWS Waxman
S Waxman
FGF González
F González
MVM L De Vicente
M L De Vicente
Manuel Ignacio San AndresManuel Ignacio San Andres
Manuel Ignacio San Andres

1 November 2005 in The Veterinary Journal
Verified
Journal Article
Closed access
JBJose Julio de Lucas Burneo
Jose Julio de Lucas Burneo
CRCasilda Rodríguez
Casilda Rodríguez
SWSamanta Waxman
Samanta Waxman
FGFernando González
Fernando González
IUIsabel Uriarte
Isabel Uriarte
Manuel Ignacio San AndresManuel Ignacio San Andres
Manuel Ignacio San Andres

1 April 2012 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
MEM. Escribano
M. Escribano
Manuel Ignacio San AndresManuel Ignacio San Andres
Manuel Ignacio San Andres
JBJose Julio de Lucas Burneo
Jose Julio de Lucas Burneo
AGA. Gonzalez-Canga
A. Gonzalez-Canga
From a human safety perspective, the administration of ivermectin to food producing animal species entails potential risks related to the presence of drug residues in edible tissues, milk, and other derived products. The European Medicines Agency has established the maximum residue limits for ivermectin in the European Union, with values of 100 μg·kg-1 in fat and liver and 30 μg·kg-1 in kidney for all mammalian food producing species, in order to ensure that the amount of ivermectin that can be found in animal foodstuff is below dangerous levels for the consumers. According to these values, withdrawal periods after subcutaneous injection were recently established in the European Union (2009), in 49 days for products containing ivermectin as a single active substance or in combination with closantel, and in 66 days when combined with clorsulon. The marker residue for ivermectin was found to be H2B1a, which is the major component of the parent compound. The tissue distribution of residues and the overall ratios of marker to total residues were generally similar in most species, and the highest concentrations of ivermectin residues were found in fat and liver with high levels also detected in injection site muscles. Ivermectin is not licensed for use in animals from which milk is produced for human consumption, however its extra-label use should be considered regarding human safety, due to its long persistence in milk and milk-derived products.